BioSphere Medical, Inc. Announces New Journal Articles Published Discussing Uterine Fibroid Embolization

ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere” or the “Company”) – a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported two journal articles on uterine fibroid embolization (UFE): the New England Journal of Medicine has published a feature article concluding that UFE should be discussed as a choice for an appropriate patient who wishes to avoid hysterectomy for the treatment of fibroids; the American Journal of Obstetrics & Gynecology has published a review concluding that UFE is an option that all physicians may wish to discuss with all patients who are being offered surgical solutions.